{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T09:52:35Z","timestamp":1721555555965},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"s31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p id=\"P1_w2aab3b7b6b1b6b1aab1c16b1Aa\">Optimal protection against preventable diseases for adolescents can be provided through routine vaccination. Vaccinations recommended by the Advisory Committee on Immunization Practices of the Centers of Disease Control and Prevention can reduce morbidity and mortality associated with influenza, meningococcal, human papillomavirus, tetanus, diphtheria, and pertussis infections. Most reported adverse reactions to these vaccinations are mild, and the benefits of immunization often outweigh the potential risks. In the present article, the authors discuss adverse events, contraindications, and precautions associated with adolescent immunizations.<\/jats:p>","DOI":"10.7556\/jaoa.2014.044","type":"journal-article","created":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T21:55:17Z","timestamp":1393019717000},"page":"13-17","source":"Crossref","is-referenced-by-count":2,"title":["Adverse Effects of Adolescent Immunizations"],"prefix":"10.1515","volume":"114","author":[{"given":"Natalia","family":"Vernon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"2021042020250769516_j_jaoa.2014.044_ref_001_w2aab3b7b6b1b6b1ab2b1b1Aa","unstructured":"Recommended immunizations for children from 7 through 18 years old. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/vaccines\/who\/teens\/downloads\/parent-version-schedule-7-18yrs.pdf. Accessed November 1, 2013."},{"issue":"RR-2","key":"2021042020250769516_j_jaoa.2014.044_ref_002_w2aab3b7b6b1b6b1ab2b1b2Aa","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","year":"2011","journal-title":"MMWR Recomm Rep."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_003_w2aab3b7b6b1b6b1ab2b1b3Aa","unstructured":"Adacel [package insert]. Swiftwater, PA: Sanofi Pasteur; April2013. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM142764.pdf. Accessed November 1, 2013."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_004_w2aab3b7b6b1b6b1ab2b1b4Aa","unstructured":"Boostrix [package insert]. Research Triangle Park, NC: GlaxoSmithKline. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/UCM152842.pdf. Accessed November 1, 2013."},{"issue":"1","key":"2021042020250769516_j_jaoa.2014.044_ref_005_w2aab3b7b6b1b6b1ab2b1b5Aa","first-page":"13","article-title":"Updated recommendations for the use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_006_w2aab3b7b6b1b6b1ab2b1b6Aa","unstructured":"Menomune [package insert]. Swiftwater, PA: Sanofi Pasteur; October2012. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM308370.pdf. Accessed November 1, 2013."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_007_w2aab3b7b6b1b6b1ab2b1b7Aa","unstructured":"Menactra [package insert]. Swiftwater, PA: Sanofi Pasteur; April2013. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM131170.pdf. Accessed November 1, 2013."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_008_w2aab3b7b6b1b6b1ab2b1b8Aa","unstructured":"Menveo [package insert]. Cambridge, MA: Novartis; August2013. http:\/\/www.fda.gov\/downnloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UMC201349.pdf. Accessed November 1, 2013."},{"issue":"RR-2","key":"2021042020250769516_j_jaoa.2014.044_ref_009_w2aab3b7b6b1b6b1ab2b1b9Aa","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_010_w2aab3b7b6b1b6b1ab2b1c10Aa","unstructured":"Gardasil [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2010. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM111263.pdf. Accessed November 1, 2013."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_011_w2aab3b7b6b1b6b1ab2b1c11Aa","unstructured":"Cervarix [package insert]. Research Triangle Park: GlaxoSmithKline; 2012. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM186981.pdf. Accessed November 1, 2013."},{"issue":"RR-2","key":"2021042020250769516_j_jaoa.2014.044_ref_012_w2aab3b7b6b1b6b1ab2b1c12Aa","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep."},{"issue":"50","key":"2021042020250769516_j_jaoa.2014.044_ref_013_w2aab3b7b6b1b6b1ab2b1c13Aa","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males\u2014Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"suppl 1","key":"2021042020250769516_j_jaoa.2014.044_ref_014_w2aab3b7b6b1b6b1ab2b1c14Aa","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons ages 0 through 18 years and adults aged 19 years and older\u2014United States, 2013","volume":"62","year":"2013","journal-title":"MMWR Surveill Summ."},{"issue":"4","key":"2021042020250769516_j_jaoa.2014.044_ref_015_w2aab3b7b6b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1542\/peds.2012-2308","article-title":"Recommendations for prevention and control of influenza in children, 2012-2013","volume":"130","year":"2012","journal-title":"Pediatrics"},{"key":"2021042020250769516_j_jaoa.2014.044_ref_016_w2aab3b7b6b1b6b1ab2b1c16Aa","unstructured":"Flumist [package insert]. Gaithersburg, MD: MedImmune; 2012. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM123743.pdf. Accessed December 13, 2013."},{"issue":"RR-7","key":"2021042020250769516_j_jaoa.2014.044_ref_017_w2aab3b7b6b1b6b1ab2b1c17Aa","first-page":"1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2013-2014","volume":"62","year":"2013","journal-title":"MMWR Recomm Rep."},{"key":"2021042020250769516_j_jaoa.2014.044_ref_018_w2aab3b7b6b1b6b1ab2b1c18Aa","unstructured":"Fluarix Quadrivalent [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM220624.pdf. Accessed November 5, 2013."},{"issue":"1","key":"2021042020250769516_j_jaoa.2014.044_ref_019_w2aab3b7b6b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol."},{"issue":"2","key":"2021042020250769516_j_jaoa.2014.044_ref_020_w2aab3b7b6b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis."},{"issue":"4","key":"2021042020250769516_j_jaoa.2014.044_ref_021_w2aab3b7b6b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain-Barr\u00e9 syndrome [review]","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf."},{"issue":"1","key":"2021042020250769516_j_jaoa.2014.044_ref_022_w2aab3b7b6b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CND.0b013e3181aaa968","article-title":"Guillain-Barr\u00e9 syndrome after vaccination in the United States: data from the Centers for Disease Control and Prevention\/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005)","volume":"11","author":"Souayah","year":"2009","journal-title":"J Clin Neuromuscul Dis."}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.044\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T09:58:21Z","timestamp":1619171901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.044\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":22,"journal-issue":{"issue":"s31","published-online":{"date-parts":[[2014,3,1]]},"published-print":{"date-parts":[[2014,3,1]]}},"alternative-id":["10.7556\/jaoa.2014.044"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2014.044","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}